Genmab — April 2015
-
-
Human antibody targeting CD20 on cancerous B-cells
• Differentiated vs other CD20 mAb, targets slice of$8B market
Cancer
• Approved*
• US 1st Line CLL in combo w/ chlorambucil
• EU 1st Line CLL in combo w/ chlorambucil or
bendamustine
• Fludarabine and alemtuzumab refractory CLL
• Phase III trials in CLL & FL
• Partnered with Novartis
Autoimmune diseases (unapproved)
• Phase III trial ongoing in PV
• Relapsing remitting MS Ph III’s & pivotal NMO trials
announced
• Partnered with GSK
O -
Det satser vi på.
-
http://www.proinvestor.com/index.php?p=debat_1&postid=72159 Exiqon analyse
-
Tror nu ikke det er min analyse. Tror mere folk bare er ved at få øjnene op for aktien. Når folk kigger på casen kan de flest nok se potentialet
-
Men selvfølgelig er analysen med til at få folk til at kigge den vej.
-
Det eneste der kan bekymre mig mht. Exiqon er at jeg ikke er særlig bull på $ fremadrettet. Men det kan jo hedges
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind